Tecovirimat

證據等級: L5

預測適應症: 10 個

Tecovirimat: From Smallpox/Orthopoxvirus Infection to Hordeolum

One-Sentence Summary

Tecovirimat is a VP37 envelope protein inhibitor originally developed and FDA-authorized for smallpox and orthopoxvirus infections (including mpox), acting through a mechanism specific to the Orthopoxvirus genus. TxGNN's top-ranked prediction is Hordeolum, but the model's own mechanistic review flags this as a high embedding score with no biological plausibility, since hordeolum is a bacterial (typically staphylococcal) eyelid gland infection unrelated to poxvirus replication or budding. No clinical trials or literature support this specific pairing.

Quick Overview

Item	Content
Original Indication	Smallpox / Orthopoxvirus infection (incl. mpox), per literature context in evidence pack
Predicted New Indication	Hordeolum
TxGNN Prediction Score	99.66%
Evidence Level	L5 (model prediction only, no supporting studies)
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Tecovirimat inhibits the VP37 envelope-wrapping protein, a mechanism specific to the Orthopoxvirus genus (variola/smallpox, mpox, vaccinia). This mechanism has no known relevance to eyelid gland infections such as hordeolum, which are caused by bacteria (typically Staphylococcus aureus) infecting the meibomian or Zeis glands — an entirely different pathogen class and disease process.

The evidence pack's own mechanistic review explicitly rejects this prediction: "TxGNN's high score reflects an embedding-space coincidence, with no biological plausibility." The same pattern repeats across ranks 2–10 (vibrio infection, Klebsiella infection, noma, arbovirus infection, equine infectious anemia, idiopathic herpes, Astroviridae infection, Arterivirus infection) — all are bacterial infections, unrelated RNA/DNA virus families, or veterinary-only pathogens with no mechanistic link to VP37 inhibition.

The one exception in this candidate set is rank 5, "coinfection" (L3, S1, evidence includes 20 real publications). However, on closer reading, this cluster of literature does not represent a genuine new-indication signal — it consists of case reports and reviews describing tecovirimat's existing, already-approved use for mpox in patients with HIV or other coinfections (e.g., neurosyphilis, VZV). This appears to be a data-labeling artifact: the correct disease label should be "mpox in immunocompromised/coinfected patients," not a novel repurposing target. It should not be counted as new-indication evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for Hordeolum.

Note: 20 publications exist for rank 5 ("coinfection"), but these describe tecovirimat's already-approved mpox indication in HIV/coinfected populations rather than a novel repurposing hypothesis — see rationale above.

Germany Market Information

Tecovirimat is not currently marketed in Germany (0 authorizations on record), so no authorization table is available.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-interaction data are not yet available in this evidence pack (flagged as a Blocking data gap, DG001 — TFDA/BfArM label warnings and contraindications must be retrieved before any S1 safety screening can proceed).

Conclusion and Next Steps

Decision: Hold

Rationale: All ten TxGNN top-ranked predictions for tecovirimat lack mechanistic plausibility or supporting clinical/literature evidence. Nine of ten (hordeolum, vibrio infection, Klebsiella infection, noma, arbovirus infection, equine infectious anemia, idiopathic herpes, Astroviridae infection, Arterivirus infection) are bacterial, unrelated-virus, or veterinary conditions with no link to the VP37 orthopoxvirus mechanism. The one candidate with literature support ("coinfection") is most likely a mislabeled instance of tecovirimat's existing mpox indication in HIV-coinfected patients, not a true repurposing signal.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/BfArM label warnings and contraindications before any safety-stage (S1) review
Resolve DG002 (High): obtain formal DrugBank/FDA-label MOA documentation to properly ground future mechanistic assessments
Relabel "coinfection" in the TxGNN indication ontology as "mpox in HIV/immunocompromised patients" to avoid conflating existing-indication evidence with novel repurposing signals
Re-run TxGNN scoring excluding known off-target embedding clusters (bacterial/veterinary diseases) if this pattern recurs for other orthopoxvirus-specific antivirals
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.